
July 21 (Reuters) - Helius Medical Technologies Inc HSDT.O:
HELIUS ANNOUNCES POSITIVE OUTCOME OF THE PORTABLE NEUROMODULATION STIMULATOR PONS® STROKE REGISTRATIONAL PROGRAM AND UPCOMING SUBMISSION TO FDA UNDER BREAKTHROUGH DESIGNATION
HELIUS MEDICAL TECHNOLOGIES INC - STUDIES CONFIRM MINIMAL ADVERSE EVENTS WITH PONS THERAPY
HELIUS MEDICAL TECHNOLOGIES: PLANNING TO FILE A SUBMISSION TO FDA FOR INDICATION IN STROKE DURING Q3 OF 2025